Alzheimer's Disease Highlighted as Potential New Indication for Statin Drugs; Nymox -NASDAQ:NYMX- Holds Patent Rights to Statins in Alzheimer's.

Business Editors/Health/Medical Writers

NEW YORK--(BUSINESS WIRE)--June 26, 2003

Statin drugs for lowering cholesterol may have unexpected preventive and treatment benefits for several new indications according to recent studies. The potential benefits of statin drug use in the treatment or prevention of Alzheimer's disease was highlighted in a recent feature article in The Los Angeles Times on June 22, 2003. Other recent epidemiological studies have linked the use of statins with evidence of significant reduction of the risk of heart attack in diabetics, cardiovascular complications for kidney and heart transplant patients and cancer, in particular renal and prostate cancer, in the general population.

Nymox Pharmaceutical Corporation holds a U.S. patent and global rights for the use of statin drugs for the treatment and prevention of Alzheimer's disease.

Recently, Dr. Larry Sparks of the Roberts Laboratory for Neurodegenerative Disease presented data from extensive studies at the Fourth Manhattan Alzheimer's Disease Conference supporting the underlying mechanism for the potential value of statins in the treatment of AD.

The current global market for statins is estimated at $19 billion and to be growing at 15% per year. Alzheimer's disease is the leading cause of dementia in the elderly, afflicting an estimated 4 million people in the U.S. alone.

"These and other studies have suggested that the effects of statin drugs may go beyond the immediate benefit of lowering of cholesterol levels," said Dr. Michael Munzar, Medical Director of Nymox. "The pace of research in this area is accelerating, particularly as the need for effective methods to prevent or delay the onset of Alzheimer's disease becomes more acute as our population ages."

Nymox's research and development programs concentrate on novel approaches to therapeutics and diagnostics with a specific focus on the diagnosis and treatment of Alzheimer's disease. Nymox offers AlzheimAlert(TM), a unique urine test designed to aid physicians in the diagnosis of Alzheimer's disease, through its Clinical Reference Laboratory in Maywood, NJ at a cost of $295. Nymox has several major proprietary drug development programs with candidate drugs for Alzheimer's disease. One major drug discovery platform targets neural thread protein, the brain protein detected by Nymox's AlzheimAlert(TM) test and implicated in the Alzheimer's disease process. Another targets spherons, tiny balls of densely packed protein found scattered in human brain cells from an early age.

More information about Nymox is available at www.nymox.com, email: [e-mail], or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.